San Francisco, CA, United States of America

Isin N Geren

This inventor holds 6 USPTO granted patents and 1 published patent application and 1 EPO patent. Top assignee: University of California. Active years: 2010-2020.

USPTO Granted Patents = 6 

% Patents Active = 100.0


Average Co-Inventor Count = 2.8

ph-index = 5

Forward Citations = 73(Granted Patents)


Location History:

  • San Francisco, CA (US) (2010 - 2019)
  • Redwood City, CA (US) (2013 - 2020)

Company Filing History:


Years Active: 2010-2020

Loading Chart...
Loading Chart...
6 patents (USPTO):Explore Patents

Title: Innovations of Isin N Geren in Therapeutic Antibodies

Introduction

Isin N Geren is a prominent inventor based in San Francisco, CA. He has made significant contributions to the field of biotechnology, particularly in the development of therapeutic monoclonal antibodies. With a total of six patents to his name, Geren's work focuses on neutralizing botulinum neurotoxins, which are critical in the treatment of botulism.

Latest Patents

Geren's latest patents include innovative therapeutic monoclonal antibodies that specifically bind to and neutralize botulinum neurotoxins, such as BoNT/A, BoNT/B, and BoNT/E. These inventions provide antibodies that can effectively neutralize these neurotoxins, making them valuable in medical treatments for botulism. The antibodies and their derivatives are designed to target the neutralizing epitopes, ensuring their efficacy in therapeutic applications.

Career Highlights

Isin N Geren is affiliated with the University of California, where he conducts his research and development work. His career is marked by a commitment to advancing medical science through innovative solutions. His contributions have been recognized in the field, and he continues to push the boundaries of what is possible in therapeutic interventions.

Collaborations

Geren has collaborated with notable colleagues, including James David Marks and Jianlong Lou. These partnerships have enhanced his research efforts and contributed to the successful development of his patented technologies.

Conclusion

Isin N Geren's work in developing therapeutic monoclonal antibodies represents a significant advancement in the fight against botulism. His innovative patents and collaborations highlight his dedication to improving medical treatments and outcomes.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…